Printer Friendly

Moberg Derma completes patient recruitment for Limtop Phase II study in AK.

M2 EQUITYBITES-September 6, 2012-Moberg Derma completes patient recruitment for Limtop Phase II study in AK(C)2012 M2 COMMUNICATIONS

Moberg Derma AB (STO:MOB.ST) said today that it has successfully completed the recruitment of 97 patients with Actinic Keratosis (AK) on the head or face for the ongoing Limtop phase II study.

The aim of the study is to evaluate the efficacy and safety of three different dose regimens of Limtop. The results are expected in the first half of 2013.

Limtop is a formulation of imiquimod for the treatment of actinic keratosis, genital warts and basal cell cancer. The objective is a product with short treatment duration, improved safety profile and similar or better efficacy than that of competing preparations, the company said.

Moberg Derma develops patented topical pharmaceuticals.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 6, 2012
Previous Article:OECD lowers forecast for UK economy in 2012.
Next Article:Navidea Biopharmaceuticals Inc names Dr. Cornelia Reininger as chief medical officer.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters